Drug safety in pregnancy: the German Embryotox institute

• Published in: European journal of clinical pharmacology 2018-02, Vol.74 (2), p.171-179
• Main Authors: Dathe, Katarina, Schaefer, Christof
• Format: Article
• Language: English
• Subjects: Adverse Drug Reaction Reporting Systems - organization & administration; Aldosterone; Angiotensin; Biomedical and Life Sciences; Biomedicine; Databases, Pharmaceutical - statistics & numerical data; Embryology; Female; Genetics; Humans; Obstetrics; Pharmacology/Toxicology; Pharmacovigilance; Pregnancy; Pregnancy Outcome; Product information; Product safety; Program Development; Quality control; Renin; Risk Assessment; Risk communication; Safety; Side effects; Special Article; Teratogenicity; Toxicants; Toxicity; Valproic acid
• ISSN: 0031-6970; 1432-1041
• DOI: 10.1007/s00228-017-2351-y

Since 1988, the German Embryotox institute combines individual counselling of pregnant women and their health care providers (HCP) with research on drug safety in pregnancy. In addition, Embryotox offers web-based information which covers the most important and most frequently requested pharmaceutical substances. In contrast to ready-made drug risk information in package leaflets and other product information, individual counselling considers different clinical settings such as (1) looking for a drug of choice or planning pregnancy under medication, (2) risk assessment of a particular drug that has already been taken during an (unplanned) pregnancy and (3) evaluation of an adverse pregnancy outcome in association with a particular medication. Using the three established developmental toxicants valproic acid, isotretinoin, and renin-angiotensin-aldosterone system (RAAS) inhibitors as an example, the need of detailed information is illustrated. Through the risk communication process, pregnancy outcome data are routinely collected by Embryotox. This approach uses the advantages of a pre-existing communication structure and of dealing with motivated responders. Engagement in the treatment plan facilitates receiving reliable data on drug exposure as well as detailed follow-up data. Based on these patient records, prospective datasets are evaluated in observational cohort studies in comparison to non-exposed control cohorts. In addition, retrospective datasets received as suspected adverse drug reactions from multiple German sources allow a screening for signals of teratogenicity and distinct patterns of developmental toxicity. Clinical expertise in specialties such as teratology, paediatrics, embryology, obstetrics and human genetics are required to ensure high-quality assessment of drug safety in pregnancy.